Proteome Systems Ltd (ASX:PXL) today announced the signing of an agreement with the
New York based biotechnology company, Egenix Inc to co-develop a scroteome-based (
semen-based) diagnostic kit for prostate cancer based on the known proprietary
Human Carcinoma Antigen (HCA)